Best Providers for Insurance Support
Programmes that work a prior authorisation.
Hims & Hers leads this ranking at $199 all-in monthly at a 2.4 mg maintenance dose and about $2,388 for a first year. The order is computed from the dataset on the criterion named in the title, not assigned editorially.
3 of 20 priced programmes qualify for this list; 17 are excluded because they do not meet the criterion. Programmes that publish no price we could capture cannot be ranked and are listed separately.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
Of the 32 programmes on this site, 4 have a price we read at the provider or manufacturer, 16 carry a third-party figure we have not confirmed, and 12 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
Best Providers for Insurance Support
| Programme | All-in at 2.4 mg | First year | Structure | Evidence |
|---|---|---|---|---|
| 1. Hims & Hers | $199 | $2,388 | flat at every doseno membership | third-party figure |
| 2. LifeMD | $199 | $2,388 | flat at every doseno membership | third-party figure |
| 3. Ro Body | $299 | $3,588 | flat at every doseno membership | third-party figure |
How this ranking is produced
The sort key is stated in the title and applied to the dataset. Nothing is weighted by hand, no programme pays for position, and the underlying figures are downloadable from the price index so the order can be reproduced rather than trusted. Where a programme is excluded, it is because it fails the criterion, not because of an editorial judgement about it.
What this ranking cannot tell you
Whether shipments arrive on time, whether messages get answered, or whether the clinical oversight is adequate. We hold no measurements of those we would defend, so they are absent rather than estimated. Read the individual review and run the pharmacy checks before enrolling anywhere this list surfaces.
How wide the spread actually is
Between the top and bottom of this list the difference is $1,200 on the criterion being ranked. Hims & Hers leads and Ro Body sits last among those that qualify, for the identical molecule from the same category of licensed pharmacy.
That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing, marketing cost and margin. Knowing that is what makes shopping this category worthwhile at all: there is real money on the table and no clinical reason to leave it there.
What this ranking deliberately ignores
Shipping reliability, response times, clinical depth and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent rather than estimated, and no weighting has been applied to smuggle a judgement about them into the order.
That makes this list narrower than an editorial round-up and considerably harder to dispute. It answers one question exactly, and it says which question in the title.
Using a ranking without being misled by one
Set the dose you expect to maintain on, filter to prices we verified at source, and read the individual review of anything in the top three before enrolling. A ranking is a shortlist generator, not a recommendation, and the differences that decide satisfaction are mostly not the ones a ranking can measure.
Then re-run it annually. Programmes move pricing without telling existing patients, and several tracked programmes changed rates more than once in the past year.
The same 3 programmes at every dose
A ranking sorted at one dose is a ranking of one scenario. This is the qualifying field at the starter dose, a maintenance dose and the ceiling, so you can see whether the order holds.
| Programme | At 0.25 mg | At 1 mg | At 2.4 mg | First year | Evidence |
|---|---|---|---|---|---|
| Hims & Hers | $199 | $199 | $199 | $2,388 | third-party figure |
| LifeMD | $199 | $199 | $199 | $2,388 | third-party figure |
| Ro Body | $299 | $299 | $299 | $3,588 | third-party figure |
The spread between first and last on this criterion is $1,200. Where the order changes between columns, the programme you should choose depends on a dose decision your prescriber has not made yet — which is an argument for the flat-rate options rather than for the top of this table.
What the leader is not
Hims & Hers leads on the criterion in the title. That is not a statement that it ships reliably, answers messages quickly, or provides better clinical oversight than the programme below it. We hold no measurements of any of those and will not imply otherwise by dressing a price sort as an overall verdict.
What it does mean is that on one stated, reproducible measure it comes first, and you can download the file and confirm that in under a minute.
Who this ranking is wrong for
Anyone whose binding constraint is not the one in the title. A cheapest-at-maintenance list is the wrong list for someone holding a starter dose permanently. A no-membership list is the wrong list for someone who would use unlimited clinician messaging weekly during titration.
There are more than twenty rankings on this site precisely because there is no single best programme. Pick the ranking that matches your constraint, then read the individual review.
How often this changes
Pricing in this market moved repeatedly through 2026 and five large programmes stopped selling compounded semaglutide entirely. This table regenerates from the dataset on every build rather than being edited, so it cannot silently drift, but the underlying capture date is 2026-08-05.
Treat any ranking older than a month — ours included — as needing a re-check against the provider's own page before you act on it.
How to use a ranking without being used by one
Read the criterion in the title, then check it is your criterion. This list sorts on one measure; there are more than twenty rankings here because no single measure decides a purchase.
Then read the second and third entries as seriously as the first. The gap between them is frequently smaller than the difference in what they disclose, and a programme two places down that names its pharmacy is a better purchase than the leader that does not.
Finally, check the evidence column. Hims & Hers leads here, and whether its figure was read at the provider or taken from a third party is stated in the row rather than buried in a methodology page.
Why we publish so many of these
Because a single 'best' list is a claim that everyone shares one constraint, which is obviously false. Someone holding 1 mg permanently, someone escalating to 2.4 mg, someone who cannot commit to a term and someone with a documented cardiovascular indication are four different buyers.
Splitting them into separate rankings costs us the ability to say 'the best programme is X', which is the sentence comparison sites are built to sell. It buys the reader an order that matches their situation.
If your constraint is not represented, the matrix sorts the same dataset on any column.
What would move this list
A price change we have not captured, a programme leaving the compounded market, or a figure we recorded from a third party that does not survive checking. All three happened during 2025 and 2026, and all three are logged with the date when they do.
The table regenerates from the dataset on every build rather than being edited by hand, so it cannot silently drift from the underlying record. Prices were captured 2026-08-05.
How much best providers for insurance support should weigh
Less than the dose question and more than the brand. 19 of 20 programmes hold one price from 0.25 mg to 2.4 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.
That is because semaglutide titrates slowly. Sixteen weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.
Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.
What a well-run programme publishes
Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished semaglutide base from salt forms and linked the salts to safety concerns.
That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.
What the spread actually represents
All-in cost runs $145 to $324 a month for the same molecule from the same category of licensed pharmacy. That gap is not the medicine. It is overhead, clinical wrap, sourcing and margin, plus how aggressively a programme is willing to structure its fees.
4 of 20 charge a mandatory recurring fee and 19 hold one price at every strength. Those two facts explain most of the spread, and neither appears in a headline figure.
Where our numbers could be wrong
A programme changed its price after our capture date. A third-party figure we recorded does not survive checking. A promotional rate was published as a standing one. Or a programme publishes something we could not find.
All four are live risks and the first is near-certain over time. Every figure carries its capture date and a link to the source we read, so the check takes about two minutes and does not require trusting us.
Why the cheapest entries are the least reliable
Four distortions push in the same direction: a promotional first month quoted as a standing rate, a prepaid bundle rate quoted as monthly, a medication figure that excludes a mandatory membership, and occasionally a different molecule's price in the wrong column.
Every one of those makes a programme look cheaper than it is, which is why the bottom of any published table is where errors concentrate. It is also why we mark which figures we read at the provider and which we did not, rather than presenting one confident list.
Where we have been able to check an unconfirmed figure against a provider's own page, the number usually moved upward.
How to sanity-check any figure you find elsewhere
Three questions. What dose does it describe? Does it include every recurring fee? And when was it captured? A price failing any of the three is not comparable to the numbers here, and most published figures fail at least one.
Semaglutide makes this worse than most categories because the same molecule sells under several brands at prices spanning more than fifteenfold. 'Semaglutide costs X' is not a sentence that can be true without naming the product and the channel.
The comparison most people get wrong
Almost every published semaglutide ranking sorts on advertised entry price. That figure describes the four weeks you spend at the 0.25 mg starter dose — roughly 8% of a first year. Ten of your first twelve months are spent at or near a maintenance dose, which is why every figure here is stated at 2.4 mg and why the first-year column exists.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.
Common questions
Which programme leads on providers for insurance support?
Hims & Hers at $199 all-in monthly at a 2.4 mg maintenance dose and about $2,388 for a first year. The order is computed from the dataset on the criterion in the title, not assigned.
Is this ranking paid for?
No. No programme pays for placement or position, and the order is generated from the published dataset, which is downloadable so the ranking can be reproduced.
Why are some programmes missing from this list?
Either they fail the criterion for this list, or they publish no price we could capture. The second group appears in the provider directory with an explanation instead of an estimated figure.
How current are these prices?
Captured 2026-08-05. Each row carries an evidence status saying whether we read the figure at the provider or took it from a third party.
Does the ranking change with my dose?
Yes, on any list sorted at a maintenance dose. Flat-rate programmes hold one price at every strength while dose-scaled programmes climb, so the order at 0.25 mg is frequently not the order at 2.4 mg.